HAPSTR1

Summary

HAPSTR1 (HUWE1 associated protein modifying stress responses, HGNC:30103) is a protein-coding gene on chromosome 16p13.2, encoding HUWE1-associated protein modifying stress responses 1 (Q14CZ0). Acts as a central player within a network of stress response pathways promoting cellular adaptability. It is a selective cancer dependency (DepMap: 41.4% of cell lines).

Enables ubiquitin protein ligase binding activity. Involved in negative regulation of signal transduction by p53 class mediator and regulation of cellular response to stress. Located in cytoplasm and nucleus.

Source: NCBI Gene 29035 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 12 total — 2 pathogenic
• Cancer dependency (DepMap): dependent in 41.4% of screened cell lines
• MANE Select transcript: NM_014117

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30103
Approved symbol	HAPSTR1
Name	HUWE1 associated protein modifying stress responses
Location	16p13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ41272, PRO0149, TAPR1
Ensembl gene	ENSG00000182831
Ensembl biotype	protein_coding
Entrez	29035

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000327827, ENST00000574285, ENST00000917518, ENST00000917519

RefSeq mRNA: 1 — MANE Select: NM_014117 NM_014117

CCDS: CCDS10538

Canonical transcript exons

ENST00000327827 — 4 exons

Exon	Start	End
ENSE00001301992	9092921	9093001
ENSE00001315335	9116668	9121635
ENSE00001324667	9102984	9103259
ENSE00001324927	9091644	9092270

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 53.3104 / max 608.9471, expressed in 1823 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
152675	50.1930	1821
152679	3.1174	1362

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.37	gold quality
endothelial cell	CL:0000115	98.39	gold quality
amniotic fluid	UBERON:0000173	98.27	gold quality
esophagus squamous epithelium	UBERON:0006920	98.24	gold quality
epithelial cell of pancreas	CL:0000083	98.11	gold quality
sperm	CL:0000019	97.47	gold quality
tibia	UBERON:0000979	96.76	gold quality
tibialis anterior	UBERON:0001385	96.69	gold quality
deltoid	UBERON:0001476	96.63	gold quality
oocyte	CL:0000023	96.53	gold quality
parietal pleura	UBERON:0002400	96.46	gold quality
left ventricle myocardium	UBERON:0006566	96.42	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.27	gold quality
palpebral conjunctiva	UBERON:0001812	96.17	gold quality
ileal mucosa	UBERON:0000331	96.14	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.04	gold quality
visceral pleura	UBERON:0002401	96.02	gold quality
adrenal tissue	UBERON:0018303	95.75	gold quality
germinal epithelium of ovary	UBERON:0001304	95.23	gold quality
gingival epithelium	UBERON:0001949	95.15	gold quality
myocardium	UBERON:0002349	95.13	gold quality
epithelium of nasopharynx	UBERON:0001951	95.06	gold quality
biceps brachii	UBERON:0001507	94.99	gold quality
middle temporal gyrus	UBERON:0002771	94.87	gold quality
vastus lateralis	UBERON:0001379	94.78	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	94.64	gold quality
gingiva	UBERON:0001828	94.63	gold quality
quadriceps femoris	UBERON:0001377	94.57	gold quality
cartilage tissue	UBERON:0002418	94.46	gold quality
heart right ventricle	UBERON:0002080	94.03	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.66
E-ENAD-17	no	454.19

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

249 targeting HAPSTR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-3605-5P	99.96	67.12	932

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 41.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition. (PMID:33660365)
• Telomere Attrition and p53 Response 1 (TAPR1): a new player in cancer biology? (PMID:34133663)
• C16orf72/HAPSTR1 is a molecular rheostat in an integrated network of stress response pathways. (PMID:35776542)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	hapstr1a	ENSDARG00000055383
mus_musculus	Hapstr1	ENSMUSG00000022507
rattus_norvegicus	Hapstr1	ENSRNOG00000002545
drosophila_melanogaster	CG4768	FBGN0030790
caenorhabditis_elegans	haps-1	WBGENE00016741

Paralogs (1): HAPSTR2 (ENSG00000230707)

Protein

Protein identifiers

HUWE1-associated protein modifying stress responses 1 — Q14CZ0 (reviewed: Q14CZ0)

Alternative names: Telomere attrition and p53 response 1 protein

All UniProt accessions (2): A0A087X1J2, Q14CZ0

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a central player within a network of stress response pathways promoting cellular adaptability. The E3 ligase HUWE1 assists HAPSTR1 in controlling stress signaling and in turn, HUWE1 feeds back to promote the degradation of HAPSTR1. HAPSTR1 represents a central coordination mechanism for stress response programs. Functions as a negative regulator of TP53/P53 in the cellular response to telomere erosion and probably also DNA damage. May attenuate p53/TP53 activation through the E3 ubiquitin ligase HUWE1.

Subunit / interactions. Homooligomer. Heterooligomer with HAPSTR2; the interaction is direct and stabilizes HAPSTR1. Interacts with HUWE1.

Subcellular location. Nucleus. Cytoplasm.

Post-translational modifications. Ubiquitinated by HUWE1. Promotes HAPSTR1 degradation through polyubiquitination.

Induction. Induced by specific types of stressors like DNA damage, cellular starvation and proteotoxicity.

Similarity. Belongs to the HAPSTR1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14CZ0-1	1	yes
Q14CZ0-2	2

RefSeq proteins (1): NP_054836* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029196	HAPSTR1-like	Family
IPR040308	HAPR1	Family

Pfam: PF15251

UniProt features (17 total): region of interest 5, mutagenesis site 4, compositionally biased region 3, modified residue 2, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14CZ0-F1	70.26	0.17

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 212, 167

Mutagenesis-validated functional residues (4):

Position	Phenotype
90	loss of interaction with huwe1. no effect on oligomerization. no effect on stabilization by hapstr2.
94	loss of interaction with huwe1. no effect on oligomerization.
101	loss of interaction with huwe1. no effect on oligomerization.
119	decreased interaction with huwe1. loss of oligomerization. increased proteasomal degradation. loss of stabilization by h

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 218 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, RNGTGGGC_UNKNOWN, TAATAAT_MIR126, GCM_GSPT1, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, TATTATA_MIR374, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, SRF_Q5_01, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, CTAGGAA_MIR384, SRF_C, WANG_LMO4_TARGETS_DN, KOYAMA_SEMA3B_TARGETS_UP, USF_01

GO Biological Process (2): regulation of cellular response to stress (GO:0080135), negative regulation of signal transduction by p53 class mediator (GO:1901797)

GO Molecular Function (2): ubiquitin protein ligase binding (GO:0031625), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular response to stress	1
regulation of cellular process	1
regulation of response to stress	1
signal transduction by p53 class mediator	1
regulation of signal transduction by p53 class mediator	1
negative regulation of intracellular signal transduction	1
ubiquitin-like protein ligase binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

370 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HAPSTR1	TMEM186	Q96B77	514
HAPSTR1	POLE3	Q9NRF9	487
HAPSTR1	METTL22	Q9BUU2	480
HAPSTR1	RNASEH2C	Q8TDP1	471
HAPSTR1	RNASEH2B	Q5TBB1	458
HAPSTR1	POLE4	Q9NR33	455
HAPSTR1	RNASEH2A	O75792	449
HAPSTR1	CARHSP1	Q9Y2V2	446
HAPSTR1	GLB1L3	Q8NCI6	415
HAPSTR1	LONRF3	Q496Y0	414
HAPSTR1	NTRK3	Q16288	396
HAPSTR1	NEURL1	O76050	390
HAPSTR1	TMEM114	B3SHH9	386
HAPSTR1	NTRK1	P04629	382
HAPSTR1	ATRIP	Q8WXE1	378

IntAct

12 interactions, top by confidence:

A	B	Type	Score
HAPSTR1	FAM9B	psi-mi:“MI:0915”(physical association)	0.740
HAPSTR1	INTS12	psi-mi:“MI:0915”(physical association)	0.560
HUWE1	NCOA4	psi-mi:“MI:0914”(association)	0.350
INTS12	HAPSTR1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (903): C16orf72 (Affinity Capture-MS), FAM9B (Two-hybrid), C16orf72 (Affinity Capture-RNA), C16orf72 (Synthetic Growth Defect), C16orf72 (Affinity Capture-MS), C16orf72 (Two-hybrid), C16orf72 (Negative Genetic), C16orf72 (Affinity Capture-RNA), C16orf72 (Negative Genetic), C16orf72 (Negative Genetic), C16orf72 (Negative Genetic), HUWE1 (Affinity Capture-Western), C16orf72 (Affinity Capture-Western), HUWE1 (Reconstituted Complex), HUWE1 (Affinity Capture-MS)

ESM2 similar proteins: A0AUQ6, A2BE76, O14645, O18973, O35427, O35473, O55003, O88447, O88597, P50503, Q05B58, Q12983, Q13901, Q14457, Q14AM7, Q14CZ0, Q28HY5, Q32KN2, Q32PE4, Q4A1L3, Q4A1L4, Q4A1L5, Q4R3K5, Q4R8N2, Q4RLT3, Q52LA3, Q5JSJ4, Q5NVP8, Q5R878, Q5RBU4, Q5TKA1, Q5ZHS3, Q5ZJQ3, Q68FJ8, Q6DKA1, Q6GMH0, Q6GP52, Q6PAX8, Q6X4M3, Q7TSU0

Diamond homologs: A0A7P0TBJ1, A0A804C8T0, A2BE76, Q14AM7, Q14CZ0, Q28HY5, Q6PAX8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

12 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	1
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1526499	GRCh37/hg19 16p13.2(chr16:8969780-9211161)x1	Pathogenic
625567	GRCh37/hg19 16p13.2(chr16:8839796-9728670)	Pathogenic

SpliceAI

754 predictions. Top by Δscore:

Variant	Effect	Δscore
16:9092270:GGTGA:G	donor_loss	1.0000
16:9102979:A:AG	acceptor_gain	1.0000
16:9102980:A:G	acceptor_gain	1.0000
16:9102980:ACAG:A	acceptor_loss	1.0000
16:9102981:CA:C	acceptor_loss	1.0000
16:9102982:A:AG	acceptor_gain	1.0000
16:9102982:AG:A	acceptor_loss	1.0000
16:9102983:G:GT	acceptor_gain	1.0000
16:9102983:GA:G	acceptor_gain	1.0000
16:9102983:GAA:G	acceptor_gain	1.0000
16:9102983:GAAA:G	acceptor_gain	1.0000
16:9103241:G:GT	donor_gain	1.0000
16:9103241:G:T	donor_gain	1.0000
16:9092271:G:GG	donor_gain	0.9900
16:9092906:T:TA	acceptor_gain	0.9900
16:9102981:C:G	acceptor_gain	0.9900
16:9103120:TGGAA:T	donor_gain	0.9900
16:9103170:T:TA	donor_gain	0.9900
16:9103171:A:AA	donor_gain	0.9900
16:9115001:G:GT	donor_gain	0.9900
16:9115017:G:GT	donor_gain	0.9900
16:9116664:CTAG:C	acceptor_loss	0.9900
16:9116665:TA:T	acceptor_loss	0.9900
16:9116666:AGGTC:A	acceptor_loss	0.9900
16:9116667:G:A	acceptor_loss	0.9900
16:9092907:G:A	acceptor_gain	0.9800
16:9092916:TTCAG:T	acceptor_loss	0.9800
16:9092917:TCAG:T	acceptor_loss	0.9800
16:9092919:A:AG	acceptor_gain	0.9800
16:9092920:G:GG	acceptor_gain	0.9800

AlphaMissense

1786 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:9092231:T:C	F63L	1.000
16:9092232:T:C	F63S	1.000
16:9092233:C:A	F63L	1.000
16:9092233:C:G	F63L	1.000
16:9092235:A:C	Q64P	1.000
16:9092241:C:G	S66W	1.000
16:9092244:C:A	A67D	1.000
16:9092249:G:C	A69P	1.000
16:9092256:C:A	A71D	1.000
16:9092262:T:C	L73P	1.000
16:9092953:T:A	W87R	1.000
16:9092953:T:C	W87R	1.000
16:9092955:G:C	W87C	1.000
16:9092955:G:T	W87C	1.000
16:9092962:T:C	F90L	1.000
16:9092963:T:C	F90S	1.000
16:9092964:C:A	F90L	1.000
16:9092964:C:G	F90L	1.000
16:9092971:G:C	A93P	1.000
16:9092974:G:C	A94P	1.000
16:9092975:C:A	A94D	1.000
16:9092984:T:A	V97D	1.000
16:9092993:T:C	L100P	1.000
16:9103032:G:A	G119D	1.000
16:9103064:T:A	W130R	1.000
16:9103064:T:C	W130R	1.000
16:9103089:T:A	I138N	1.000
16:9103104:T:C	L143S	1.000
16:9103235:T:C	F187L	1.000
16:9103236:T:C	F187S	1.000

dbSNP variants (sampled 300 via entrez): RS1000030161 (16:9099861 T>A), RS1000100711 (16:9103139 C>G,T), RS1000142569 (16:9117643 A>G), RS1000146903 (16:9111615 C>A,T), RS1000177771 (16:9094849 C>G,T), RS1000200697 (16:9090250 G>A), RS1000219486 (16:9099231 C>G,T), RS1000259096 (16:9117859 T>G), RS1000308301 (16:9091441 A>T), RS1000360928 (16:9120222 G>A,C), RS1000438942 (16:9108380 T>C), RS1000459844 (16:9104489 G>A), RS1000480795 (16:9116335 C>G), RS1000532339 (16:9115745 C>T), RS1000646289 (16:9116555 T>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002919_4	Colorectal cancer	5.000000e-08
GCST005312_35	Menopause (age at onset)	3.000000e-08
GCST006073_14	Tenofovir clearance in HIV infection	8.000000e-06
GCST010988_34	Adult body size	6.000000e-09
GCST011767_2	Bipolar disorder	3.000000e-09
GCST012465_31	Bipolar disorder	3.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004704	age at menopause

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	3
methylmercuric chloride	increases expression, affects cotreatment	2
2,2’,4,4’-tetrabromodiphenyl ether	increases expression, affects expression, affects methylation	2
Acetaminophen	increases expression	2
Tobacco Smoke Pollution	increases expression	2
Cyclosporine	increases expression	2
TAK-243	increases sumoylation	1
alpha-pinene	increases abundance, affects cotreatment, decreases expression	1
zinc chromate	increases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, increases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
epigallocatechin gallate	increases expression, affects cotreatment	1
chromium hexavalent ion	increases expression, increases abundance	1
pentabromodiphenyl ether	increases expression	1
deguelin	increases expression	1
K 7174	increases expression	1
fenpyroximate	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
torcetrapib	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
eprenetapopt	affects expression, affects reaction	1
PCI 5002	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Air Pollutants	increases abundance, affects cotreatment, decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1
Dimethyl Sulfoxide	decreases expression	1
Drugs, Chinese Herbal	increases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists